BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nouri YM, Kim JH, Yoon HK, Ko HK, Shin JH, Gwon DI. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Korean J Radiol 2019;20:34-49. [PMID: 30627020 DOI: 10.3348/kjr.2018.0088] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Li S, Du C, Zhang Y, Li Y, Chu L, Han X, Galons H, Zhang Y, Sun H, Yu P. Exosomes from different cells: Characteristics, modifications, and therapeutic applications. Eur J Med Chem 2020;207:112784. [PMID: 33007722 DOI: 10.1016/j.ejmech.2020.112784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
2 Ren Y, Guo Y, Chen L, Sun T, Zhang W, Sun B, Zhu L, Xiong F, Zheng C. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma. Cancer Control 2022;29:10732748221076806. [PMID: 35343254 DOI: 10.1177/10732748221076806] [Reference Citation Analysis]
3 Bzeizi KI, Arabi M, Jamshidi N, Albenmousa A, Sanai FM, Al-Hamoudi W, Alghamdi S, Broering D, Alqahtani SA. Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:6172. [PMID: 34944792 DOI: 10.3390/cancers13246172] [Reference Citation Analysis]
4 Zhou C, Shi Q, Liu J, Huang S, Yang C, Xiong B. Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel. J Hepatocell Carcinoma 2020;7:447-56. [PMID: 33409168 DOI: 10.2147/JHC.S282209] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zhang A, Xiao Z, Liu Q, Li P, Xu F, Liu J, Tao H, Feng L, Song S, Liu Z, Huang G. CaCO3 -Encapuslated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma. Adv Healthc Mater 2021;:e2100748. [PMID: 34137207 DOI: 10.1002/adhm.202100748] [Reference Citation Analysis]
6 Razi M, Jianping G, Xu H, Ahmed MJ. Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma. J Interv Med 2021;4:11-4. [PMID: 34805941 DOI: 10.1016/j.jimed.2020.10.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cho SM, Chu HH, Kim JW, Kim JH, Gwon DI. Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm. Life (Basel) 2021;11:358. [PMID: 33919658 DOI: 10.3390/life11040358] [Reference Citation Analysis]
8 Krieg S, Essing T, Krieg A, Roderburg C, Luedde T, Loosen SH. Recent Trends and In-Hospital Mortality of Transarterial Chemoembolization (TACE) in Germany: A Systematic Analysis of Hospital Discharge Data between 2010 and 2019. Cancers 2022;14:2088. [DOI: 10.3390/cancers14092088] [Reference Citation Analysis]
9 Kwak K, Yu B, Mouli SK, Larson AC, Kim DH. Sodium Cholate Bile Acid-Stabilized Ferumoxytol-Doxorubicin-Lipiodol Emulsion for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. J Vasc Interv Radiol 2020;31:1697-1705.e3. [PMID: 32773247 DOI: 10.1016/j.jvir.2020.01.026] [Reference Citation Analysis]
10 Du C, Li S, Li Y, Galons H, Guo N, Teng Y, Zhang Y, Li M, Yu P. F7 and topotecan co-loaded thermosensitive liposome as a nano-drug delivery system for tumor hyperthermia. Drug Deliv 2020;27:836-47. [PMID: 32508162 DOI: 10.1080/10717544.2020.1772409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Iezzi R, Bilhim T, Crocetti L, Peynircioglu B, Goldberg S, Bilbao JI, Sami A, Akhan O, Scalise P, Giuliante F, Pompili M, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. "Primum Non Nocere" in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications? Life (Basel) 2020;10:E180. [PMID: 32899925 DOI: 10.3390/life10090180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Inchingolo R, Spiliopoulos S, Posa A, Tibana TK, Nunes TF, Memeo R. New frontiers in endovascular therapies for locally advanced hepatocellular carcinoma. Radiol Bras 2021;54:130-5. [PMID: 33854268 DOI: 10.1590/0100-3984.2020.0027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Razi M, Safiullah S, Gu J, He X, Razi M, Kong J. Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma. Journal of Interventional Medicine 2021. [DOI: 10.1016/j.jimed.2021.12.004] [Reference Citation Analysis]
14 Chu HH, Gwon DI, Kim JH, Ko GY, Shin JH, Yoon HK. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis. AJR Am J Roentgenol 2020;215:745-52. [PMID: 32569514 DOI: 10.2214/AJR.19.21669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Chiu SH, Chang PY, Shih YL, Huang WY, Ko KH, Chang WC, Huang GS. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma. Drug Des Devel Ther 2020;14:5029-41. [PMID: 33235441 DOI: 10.2147/DDDT.S266470] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kim GH, Kim JH, Kim PH, Chu HH, Gwon DI, Ko HK. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean J Radiol 2021;22:1822-33. [PMID: 34431250 DOI: 10.3348/kjr.2021.0229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yi JW, Hong HP, Kim MS, Shin BS, Kwon H, Kim BI, Sohn W. Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. Life 2022;12:297. [DOI: 10.3390/life12020297] [Reference Citation Analysis]
18 Kuan A, Khoo L, Yang SS, Chia HY, Lee JSS. Retiform Purpura as a Complication of Microsphere Emboli Following Transarterial Chemoembolization for Primary Hepatocellular Carcinoma: A Case Report and Literature Review. The American Journal of Dermatopathology 2020;42:e108-10. [DOI: 10.1097/dad.0000000000001586] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Pérez-López A, Martín-Sabroso C, Torres-Suárez AI, Aparicio-Blanco J. Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom. Pharmaceutics 2020;12:E1028. [PMID: 33126622 DOI: 10.3390/pharmaceutics12111028] [Reference Citation Analysis]
20 Wang D, Wu Q, Guo R, Lu C, Niu M, Rao W. Magnetic liquid metal loaded nano-in-micro spheres as fully flexible theranostic agents for SMART embolization. Nanoscale 2021;13:8817-36. [PMID: 33960346 DOI: 10.1039/d1nr01268a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Duan X, Zhao G, Han X, Ren J, Li H, Chen P, Wang M, Ju S. Arsenic trioxide-loaded CalliSpheres: In vitro study of drug release and antitumor activity, and in vivo study of pharmacokinetics, treatment efficacy and safety in liver cancer. Oncol Rep 2021;46:124. [PMID: 33982781 DOI: 10.3892/or.2021.8075] [Reference Citation Analysis]
22 Chang WC, Hsu HH, Chiu SH, Huang WY, Lo CH, Lin HH, Huang PC, Shih YL, Wan YL. Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (<100 μm) Beads. J Hepatocell Carcinoma 2021;8:937-49. [PMID: 34422707 DOI: 10.2147/JHC.S319920] [Reference Citation Analysis]